Epidemiology of osteoporosis

C Holroyd, C Cooper, E Dennison - Best practice & research Clinical …, 2008 - Elsevier
Osteoporosis represents a major public health problem through its association with fragility
fractures. All osteoporotic fractures increase patient morbidity; however, fractures of the hip …

[HTML][HTML] Vitamin D supplementation in pregnancy: a systematic review.

NC Harvey, C Holroyd, G Ntani, K Javaid… - Health technology …, 2014 - europepmc.org
Background It is unclear whether or not the current evidence base allows definite
conclusions to be made regarding the optimal maternal circulating concentration of 25-hydroxyvitamin …

[HTML][HTML] Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven …

…, S Bugatti, M Bellan, M Congia, C Holroyd… - The Lancet, 2021 - thelancet.com
Background Although targeted biological treatments have transformed the outlook for
patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is …

[HTML][HTML] Rheumatoid arthritis: the impact of mental health on disease: a narrative review

MN Lwin, L Serhal, C Holroyd, CJ Edwards - Rheumatology and therapy, 2020 - Springer
Over 60% of rheumatoid arthritis (RA) patients achieve a good response after 12 months of
treatment when following the European league against rheumatism (EULAR) guidelines for …

Rheumatoid arthritis in the elderly: characteristics and treatment considerations

L Serhal, MN Lwin, C Holroyd, CJ Edwards - Autoimmunity reviews, 2020 - Elsevier
The elderly rheumatoid arthritis (RA) population consists of both elderly-onset RA that manifests
after the age of 60 and individuals diagnosed with RA early in life who age naturally to …

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis

CR Holroyd, R Seth, M Bukhari, A Malaviya… - …, 2019 - academic.oup.com
… A Guideline Working group (GWG) was created, consisting of a chair, Dr Chris Holroyd,
alongside representatives from relevant stakeholders (Table 2). In accordance with BSR policy, …

[HTML][HTML] Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic

…, L Kay, P Lanyon, B Griffiths, C Holroyd… - Clinical …, 2020 - ncbi.nlm.nih.gov
Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are
often immunosuppressed and at high risk of infections. The current COVID-19 pandemic …

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis—executive summary

CR Holroyd, R Seth, M Bukhari, A Malaviya… - …, 2019 - academic.oup.com
Christopher R Holroyd , Christopher R Holroyd … Correspondence to: Christopher Holroyd,
Rheumatology Department, University Hospital Southampton, Tremona Road, Southampton, …

Lupus, vaccinations and COVID-19: what we know now

A Mason, H Anver, M Lwin, C Holroyd, SN Faust… - Lupus, 2021 - journals.sagepub.com
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus causing
Coronavirus disease 2019 (COVID-19), has had a huge impact on health services, with a high …

[HTML][HTML] Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label …

…, C Mosanya, C Buckley, C Holroyd… - The Lancet …, 2023 - thelancet.com
Background Despite highly effective targeted therapies for rheumatoid arthritis, about 40%
of patients respond poorly, and predictive biomarkers for treatment choices are lacking. We …